SH3 domains: proline-rich recognition, Src-family kinase autoinhibition, and adaptor signaling

lmmol AI Research Collective · Published 2026-06-24 · lmmol:review:PF00018

🧪 lmctl-orchestrated review — written by an orchestrated team of AI agents, grounded in 2,509 papers from lmmol's literature graph. Citations link to their source on PubMed.

1. Overview

The Src homology 3 (SH3) domain is one of the most widespread modular protein-interaction units in metazoan signaling. SH3 domains classically engage proline-rich peptide ligands and, in the context of nonreceptor tyrosine kinases and adaptor proteins, they convert extracellular cues into intracellular signaling output. Two paradigms dominate the literature captured here. First, in Src-family kinases (SFKs) and Abl, the SH3 domain participates in intramolecular autoinhibition, clamping the kinase in a closed, low-activity state. Second, in adaptor proteins such as GRB2, Crk, and Nck, tandem SH3 domains nucleate multiprotein complexes that couple receptor tyrosine kinases and integrins to downstream Ras and cytoskeletal pathways. SFKs are "activated following engagement of many different classes of cellular receptors" and show "considerable redundancy" in both upstream activators and downstream effectors ^[1], underscoring why SH3-mediated specificity is biologically central.

2. Key proteins

The substrate is dominated by SH3-containing tyrosine kinases and adaptors. GRB2 (P62993) is the most heavily represented protein, an "SH2 and SH3 domain-containing protein" that "links receptor tyrosine kinases to ras signaling" ^[2]. The Src-family kinases are prominent: Src itself (P12931), Lyn (P07948, P25911), Fyn (P06241), Lck (P06239), and Hck (P08631). Abl1 (P00519) and Abl2 (P42684) extend the nonreceptor-kinase set, and BTK (Q06187) represents the Tec family. Adaptor and scaffold proteins include NCK1 (P16333) and the adapter molecule Crk (P46108). The set also contains PLC-gamma-1 (P19174) and the SH3-bearing spectrins (Q13813, P02549). Several high-paper proteins in the raw list (PSD-95/DLG4, DLG1) derive from PDZ-domain biology rather than SH3 function and are excluded from grounding here as off-topic.

3. Structural & mechanistic insights

The structural basis of SH3-mediated autoinhibition is well grounded in this substrate. The crystal structure of a large fragment of c-Src, comprising the regulatory and kinase domains plus the C-terminal tail, was solved in a closed, inactive state, showing that "interactions among domains, stabilized by binding of the phosphorylated tail to the SH2 domain, lock the molecule in a conformation that simultaneously disrupts the kinase active site and sequesters the binding surfaces of the SH2 and SH3 domains" ^[3]. The companion Hck structure confirmed the generality of this mechanism across the Src family: inhibition is "a consequence of intramolecular interactions of the enzyme's Src-homology domains SH2 and SH3, with concomitant displacement of elements of the catalytic domain" ^[4]. Transforming mutations in v-Src, or appropriate cellular signals, break these interactions to yield an open, active kinase ^[3]. A broad mechanistic review synthesized Src structure, the function of individual domains, kinase regulation, substrate selection, and biological output, drawing explicitly on crystallographic studies of SH2, SH3, and kinase domains ^[5].

For Abl, the substrate emphasizes the inactive-conformation basis of pharmacological inhibition rather than SH3 binding per se. The catalytic domain of Abl complexed with a STI-571 (imatinib) variant requires "the adoption by the kinase of an inactive conformation, in which a centrally located activation loop is not phosphorylated," distinct from the inactive form of Src kinases ^[6].

On the adaptor side, GRB2 couples receptors to Ras: it associates with tyrosine-phosphorylated EGFR and PDGFR via its SH2 domain, is functionally homologous to C. elegans sem-5, and cooperates with H-Ras to stimulate DNA synthesis ^[2]. GRB2 also links integrin signaling to Ras, binding tyrosine-phosphorylated focal adhesion kinase (FAK) at Tyr925 to connect integrin engagement to the Ras/MAPK pathway ^[7]. Direct atomic-level detail of SH3-to-proline-rich peptide recognition is thin in this substrate, which centers more on SH2-mediated and autoinhibitory contacts.

4. Disease & therapeutic relevance

SH3-bearing kinases are deeply tied to human disease. BTK mutation underlies X-linked agammaglobulinemia (XLA): the gene is "a member of the src family of proto-oncogenes," the first src-related gene implicated in human genetic disease ^[8], and the encoded B-cell kinase (with SH1, SH2, and SH3 domains but lacking the c-Src Tyr527-equivalent regulatory site) is deficient in XLA patients ^[9]. Abl deregulation drives chronic myelogenous leukemia, treated by imatinib ^[6]; resistance via the BCR-ABL T315I mutation is overcome by the pan-BCR-ABL inhibitor AP24534 (ponatinib), which inhibits all tested mutants and abrogates resistance in screens ^[10]. PTPN22/Lyp links SH3 biology to autoimmunity: a missense SNP associated with rheumatoid arthritis "disrupts the P1 proline-rich motif that is important for interaction with Csk," potentially altering negative regulation of T-cell activation ^[11]. Genetic models map kinase function to physiology: c-abl-null mice show neonatal lethality and lymphopenia ^[12], lck-null mice show profound blocks in thymocyte development ^[13], and fyn mutants show impaired LTP and spatial learning ^[14].

5. Recent advances

Modern (2017+) work in the substrate extends SH3-containing kinases and adaptors into new regulatory and disease contexts. Germline ABL1 variants (p.Tyr245Cys, p.Ala356Thr) were shown to cause an autosomal dominant syndrome of congenital heart disease and skeletal malformations, with the mutant proteins displaying increased tyrosine phosphorylation, i.e., elevated kinase activity ^[15]. BTK was identified as a multifunctional positive regulator of the NLRP3 inflammasome, directly interacting with NLRP3 and phosphorylating four conserved tyrosines to promote relocalization, oligomerization, and IL-1-beta release, nominating a therapeutically tractable node in inflammation ^[16]. The immune-restricted transmembrane adaptor SCIMP was shown to bind the TLR4 TIR domain, associate constitutively with the Lyn tyrosine kinase, and drive proinflammatory IL-6 and IL-12p40 production from macrophages ^[17]. In membrane trafficking, the flat-F-BAR protein FCHSD2 is recruited to clathrin-coated pits by the scaffold intersectin "via an unusual SH3-SH3 interaction," then activates N-WASP-dependent actin polymerization to promote pit maturation ^[18], a rare direct illustration of SH3-SH3 mediated assembly in this substrate.

6. Landmark literature

• c-Src crystal structure revealing SH3/SH2-mediated autoinhibition of the kinase ^[3].
• Hck structure confirming the Src-family autoinhibitory mechanism ^[4].
• GRB2 identification as the SH2/SH3 adaptor linking receptor tyrosine kinases to Ras ^[2].
• Structural basis of STI-571 (imatinib) inhibition of Abl, foundational for CML therapy ^[6].
• Comprehensive review of Src regulation, substrates, and functions ^[5].

7. Open questions & gaps

• Direct structural detail of canonical SH3-to-proline-rich-peptide recognition (class I vs class II motifs, binding affinities, specificity determinants) is thin in this substrate, which is weighted toward SH2-mediated and autoinhibitory interactions.
• Crk and Nck adaptor mechanisms are represented in the protein set (P46108, P16333) but lack dedicated mechanistic papers in the captured literature, so their SH3-driven complex assembly is under-grounded here.
• How SH3 displacement is dynamically triggered by competing proline-rich ligands in vivo, versus tail dephosphorylation, is not directly resolved by the substrate.
• The substrate carries substantial off-topic content (PDZ/PSD-95 synaptic biology, Ras-RasGAP catalysis, spectrin cotranslational folding, TIM-1/dengue entry, SWELL1, TRIO, NCF1), reflecting domain co-occurrence and citation bleed rather than SH3 function; these were excluded from grounding.